Library
Celyad Announces October and November 2019 Investor Conference Schedule
Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting
Celyad to Present Update on mCRC Clinical Program at the 2019 SITC Annual Meeting
Celyad Announces Closing of $20 Million Global Offering
Celyad Announces Closing of $20 Million Global Offering
Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy
Understanding the expression profile of NKG2D ligands on T cells: Implications for CAR T cell therapy
The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy
The targeted knockdown of CD3ζ by shRNA as a platform to develop allogeneic CAR T cell therapy
Celyad Announces Pricing of $20.0 Million Global Offering
Celyad Announces Pricing of $20.0 Million Global Offering
Celyad Announces Launch of Proposed Global Offering
Celyad Announces Launch of Proposed Global Offering
Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process
Celyad Successfully Doses First Patient with CYAD-01 Produced with OptimAb Manufacturing Process
Celyad to Participate in Upcoming September 2019 Conferences
Celyad to Participate in Upcoming September 2019 Conferences
Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights
Celyad Reports Half Year 2019 Financial Results and Second Quarter Business Highlights
Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call
Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call
Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer
Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR T therapy in metastatic colorectal cancer